Can a patient who previously had an elevated hematocrit while on testosterone and now has a normal hematocrit safely restart testosterone therapy?

Can This Patient Restart Testosterone Therapy?

Yes, this patient can restart testosterone therapy now that his hematocrit has normalized to 45%, but you must implement specific monitoring protocols and consider dose/formulation adjustments to prevent recurrence of erythrocytosis.

Guideline-Based Approach to Restarting Therapy

The 2018 Endocrine Society guidelines provide clear direction: when hematocrit exceeds 54%, stop therapy until it decreases to a safe level, then reinitiate with a reduced dose 1. Your patient's hematocrit of 45% is well below this threshold and within normal range, making him eligible to restart.

Critical Monitoring Requirements

Before and after restarting testosterone:

• Check hematocrit at 3-6 months after reinitiating therapy, then annually 1
• Evaluate for underlying causes of his previous elevation: assess for hypoxia, sleep apnea, chronic lung disease, or smoking 1
• Monitor mid-cycle testosterone levels to avoid supraphysiologic peaks that drive erythrocytosis 2

Formulation Matters Significantly

The route of administration dramatically affects erythrocytosis risk, and this is where you can make the biggest impact:

Injectable Testosterone (Highest Risk)

• Intramuscular testosterone enanthate/cypionate causes erythrocytosis in 43.8% of patients 2
• Associated with supraphysiologic testosterone peaks that stimulate erythropoiesis 2
• If using injectables, consider weekly rather than every-two-week dosing to reduce peak-trough variation 3
• Starting with reduced dose (e.g., 100 mg every 2 weeks instead of 200 mg) significantly decreases hematocrit rise 4

Transdermal Preparations (Lower Risk)

• Nonscrotal patches: only 15.4% develop elevated hematocrit 2
• Intranasal testosterone actually decreased hematocrit by 0.8% in one matched cohort study 5
• Gels show dose-dependent risk: 2.8% at 5mg/day vs 17.9% at 10mg/day 2

Specific Restart Strategy

I recommend restarting with either:

1. Transdermal gel or intranasal formulation if previously on injections, OR
2. Reduced-dose injectable testosterone (50-100 mg weekly instead of 200 mg every 2 weeks) if patient prefers injections 4, 3

Additional Considerations

Dihydrotestosterone Connection

Men who develop erythrocytosis have significantly higher DHT levels (605 vs 436 ng/dL) 6. If erythrocytosis recurs despite dose reduction:

• Consider adding a 5α-reductase inhibitor (finasteride/dutasteride)
• Only 2% of men with significant hematocrit elevation were on 5α-reductase inhibitors vs 15% without elevation 6

Common Pitfall to Avoid

Do not restart at the same dose and formulation that caused HCT of 58%. The FDA label explicitly states "if restarted, a lower dosage should be utilized" 7. Most erythrocytosis occurs in the first 3-6 months 2, so your monitoring window is critical.

Hematocrit Threshold for Action

• Stop therapy if HCT reaches 54% 1
• The previous HCT of 58% was dangerously elevated and appropriately required cessation
• Current HCT of 45% provides adequate safety margin for restart

Monitoring Algorithm After Restart

Month 3-6: Check hematocrit, testosterone level (timing depends on formulation per 1)

• If HCT >52%: reduce dose or increase injection frequency
• If HCT >54%: stop therapy, evaluate for secondary causes

Month 12 and annually thereafter: Hematocrit, testosterone level, symptom assessment 1

The key is that dose reduction or formulation change is mandatory - simply restarting at the previous regimen will likely reproduce the erythrocytosis that required stopping therapy initially.